

Schep nooit een probleem,

Waar je nog geen oplossing voor hebt.



6

Single nucleotide polymorphisms in Toll-like receptor 9 are highly associated with susceptibility to bacterial meningitis in children

Gijs Th. J. van Well*,
Marieke S. Sanders*,
Sander Ouburg,
Patric S.J. Lundberg,
A. Marceline van Furth,
Servaas A. Morré

(Clinical Infectious Diseases 2011; 52(4): 475–480)

** authors attributed equally to this paper*

ABSTRACT

Bacterial meningitis (BM) is a severe infection mainly caused by *Streptococcus pneumoniae* and *Neisseria meningitidis* (NM). However, genetically determined susceptibility to develop severe infections by these microorganisms is variable between individuals. Toll-like receptor 9 (*TLR9*) recognizes bacterial DNA leading to intracellular inflammatory signaling. Single nucleotide polymorphisms (SNPs) within the *TLR9* gene are associated with susceptibility to several diseases, but no such association with meningitis has been described.

We studied the role of *TLR9* SNPs in host defense against BM. Two *TLR9* SNPs and four *TLR9* haplotypes were determined in 472 survivors of BM and compared to 392 healthy controls.

Carriage of the *TLR9* +2848-A mutant was significantly decreased in meningococcal meningitis (MM) patients compared with controls ($p = 0.0098$, OR 0.6, 95% CI 0.4–0.9). *TLR9* haplotype I was associated with an increased susceptibility to MM ($p = 0.0237$, OR 1.3, 95% CI 1.0–1.5). *In silico* analysis shows a very strong immune-inhibitory potential for DNA of NM upon recognition by *TLR9* (CpG index of -106.8).

We report an association of *TLR9* SNPs with susceptibility to BM, specifically MM indicating a protective effect for the *TLR9* +2848-A allele. We hypothesize that the *TLR9* +2848-A mutant results in an upregulation of *TLR9* induced immune response compensating the strong inhibitory potential of NM CpG DNA.

BACKGROUND

Bacterial meningitis (BM) is a serious, life-threatening infectious disease of the central nervous system (CNS) that often occurs in young children. Despite adequate antibiotic treatment and the use of adjunctive therapy such as corticosteroids, the rates of mortality and morbidity remain high [1]. The two most common pathogens causing BM in children in the Western world are *Streptococcus pneumoniae* (SP) and *Neisseria meningitidis* (NM). The incidence of BM, defined as bacteria isolated from the cerebrospinal fluid (CSF), was 1.2 per 100 000 inhabitants for pneumococcal meningitis (PM) and 0.4 per 100 000 for meningococcal meningitis (MM) in 2008 in the Netherlands [2] but is much higher in developing countries [3] where immunization rates are low.

A crucial step in the first-line defense against BM is the recognition of bacteria by innate immune mechanisms, using pathogen recognition receptors (PRRs) expressed on antigen presenting and phagocytic cells present in neural structures and non-neural structures (including macrophages and dendritic cells) in direct contact with the CSF [4]. Toll-like receptors (TLRs) are a key example of those PRRs. Within the CNS, TLRs are expressed on antigen presenting astrocytes and monocyte derived microglia [5]. *TLR9* is an intracellular PRR that recognizes unmethylated Cytosine-phosphate-Guanine (CpG) motives in bacterial and viral DNA. Binding of *TLR9* to non-self DNA triggers a cascade of intracellular receptor signaling, finally resulting in transcription of nuclear factors and the production of pro- and anti-inflammatory cytokines [6].

Single nucleotide polymorphisms (SNPs) have been identified in different TLR genes, and they affect the susceptibility to and severity of several inflammatory diseases [7, 8]. For example, the *TLR4* +896 A > G (Asp299Gly) SNP causes hyporesponsiveness to lipopolysaccharide (LPS), an important content in the membrane of NM and has been shown to enhance susceptibility to NM infections [9, 10]. Smirnova *et al.* examined a large group (n = 230) of patients with meningococcal sepsis and compared the frequency of *TLR4* coding changes to those in an ethnically matched control group (n = 421). They observed that rare heterozygous missense mutations of *TLR4* significantly contribute to the risk of developing meningococcal sepsis in a white population ($p = 2.3 \times 10^{-6}$, odds ratio [OR] 27.0) [10]. Yuan *et al.* compared SNPs in *TLR2* and *TLR4* between children with invasive pneumococcal disease and healthy blood donors and concluded that the prevalence of the *TLR4* +896 A > G/ *TLR4* +1196 C > T SNPs was significantly lower in patients than in controls ($p < 0.05$, OR 0.3, 95% CI 0.1 – 1) [11]. TLR mediated activation by interleukin-1 receptor-associated kinase 4 (IRAK4) is an important enzyme in the functioning of TLRs [12]. Eight different *IRAK4* SNPs are associated with recurrent pneumococcal disease and some with meningococcal

disease, characterized by the absence of fever and unresponsiveness to LPS in *in vitro* whole blood tests [7]. One Gambian study on meningitis exclusively did not show an association between *TLR4* +896 A > G SNPs and susceptibility to MM during epidemics in children (n = 50) [13].

Genetically determined defects in innate immunity have been described in both meningococcal and pneumococcal infections within families. A large sibling study in UK whites showed that host genetic factors contribute up to one-third to the susceptibility to meningococcal disease [14]. Although many studies on genetic variation in TLRs and infections with SP and NM have been described, studies focusing on meningitis exclusively are rare.

The aim of this study is to investigate the role of *TLR9* SNPs in the susceptibility to PM and MM. *TLR9* SNPs have been associated with the susceptibility to pouchitis, systemic lupus erythematosus, atherosclerosis, and asthma [8, 15], but no association of *TLR9* SNPs with BM or meningococcal and pneumococcal infections has been described. We hypothesized that SNPs in *TLR9* genes might change the recognition of CpG motifs in bacteria causing BM, leading to a decreased or increased susceptibility to PM and MM. To investigate the role of *TLR9* SNPs in susceptibility to BM, we compared the frequencies of *TLR9* SNPs, representing *TLR9* +2848 and *TLR9* -1237 and their haplotypes, in survivors of BM (n = 472) with those in healthy controls (n = 392) without a known history of BM. To determine the importance of the CpG in SP and NM and its immunostimulatory ability, we also performed an *in silico* analysis, a computer-based scan of bacterial genomes for stimulatory and inhibitory CpG motives.

MATERIALS AND METHODS

Patients

The study population consists of 472 Dutch white school-aged children and adolescents who survived PM or MM. These former patients were selected from data on bacterial CSF isolates of the Netherlands Reference Laboratory for Bacterial Meningitis. The mean age of infection was 2 years. Of the 472 participating children, 83 (17.6%) had PM and 389 (82.4%) had MM. In total, 397 children had meningitis between January 1990 and December 1995, and this cohort was described in detail by Koomen *et al.* [16–18]. A similar cohort of 75 children had BM between 1997 and 2001. Children with “complex onset” of meningitis (defined as: meningitis secondary to immune deficiency states, CNS surgery, cranial trauma or CSF shunt infections or relapsing meningitis) were excluded (14 patients [3%]).

Controls

The control group consists of 392 healthy adult Dutch whites without a known history of BM. Serum samples were taken from healthy employees of the VU University Medical Center in Amsterdam and the Erasmus University in Rotterdam, both in The Netherlands. Since the SNPs studied are stable over ages, no age-matched controls were needed.

Patients were mailed and asked to return a sterile swab after collecting their buccal DNA. Of these patients, 472 (71.9% of all patients who were asked to participate) returned the swab and an informed consent form. The Medical Ethical Committee of the VU University Medical Center approved this study.

DNA isolation

DNA was isolated from the buccal swabs using the following procedure: after addition of 250 μ L 10 mmol/L Tris-HCl (pH 7.4) the sample was heated at 96 degrees Celsius for 10 minutes. After mixing for 10 seconds the swabs were removed and the sample was centrifuged (14.000 rpm). In controls, venous blood (5–10 mL) was drawn and genomic DNA was isolated using standard protocols; 5–100 ng of genomic DNA was used each cycle of genotyping.

Genotyping

The polymorphisms were analyzed by TaqMan analysis using the standard TaqMan protocol. The AbiPrism 7000 Sequence Detection System (Applied Biosystems) was used to obtain data. Primer and probes used for *TLR9* -1237 were: forward primer 5'-GGCCTTGGGATGTGCTGTT-3' and reverse primer 5'-GGTGACATGGGAG-CAGAGACA-3' and dual-labeled fluorogenic hybridization MGB-probes CTGCCT-GAAAAC-5' Fluor Label (FAM, 6-carboxyfluorescein) and CTGGAAAACCCCC-5' Fluor Label (VIC). The primers and probes used for *TLR9* +2848 were: forward primer 5'-CCGCTGTGCAGGTGCTAGAC-3' and reverse primer 5'-CCAAAGGGCTGGCT-GTTGTA-3' and dual labeled fluorogenic hybridization MGB probes AGCTACCGC-GACTGG-5' Fluor Label (FAM) and AGCTACCACGACTGGA-5' Fluor Label (VIC).

Haplotypes

The two *TLR9* SNPs we analyzed were chosen on the basis of a study by Lazarus *et al.* [19] in which a set of 4 frequent *TLR9* SNPs (*TLR9* -1486, *TLR9* -1237, *TLR9* +1174, and *TLR9* +2848) was described. Genotyping of both *TLR9* -1237 T > C (NCBI SNP CLUSTER ID: rs5743836) and *TLR9* +2848 G > A (NCBI SNP CLUSTER ID: rs352140) allows all 4 locus haplotypes to be distinguished. (Haplotype I: -1486T/-1237T/+1174A/+2848G, Haplotype II: -1486C/-1237T/+1174G/+2848A, Haplotype III: -1486T/-1237C/+1174G/+2848A, Haplotype IV: -1486T/-1237C/+1174G/+2848G

or -1486C/-1237T/+1174G/+2848G or -1486C/-1237C/+1174G/+2848G or -1486T/-1237T/+1174G/+2848A. *TLR9* haplotypes were inferred using PHASE v2.1.1 [20, 21] and SNP-HAP [22].)

Statistics

Genotypes were compared between cases and controls for the PM and MM group separately and for all cases of BM. Hardy-Weinberg tests were used to test for Mendelian inheritance. Fisher exact test and χ^2 test were employed where appropriate. P values < 0.05 were considered statistically significant.

In silico analysis

To determine the immunostimulatory ability of the CpG DNA in SP and NM we performed an *in silico* analysis as described by Lundberg *et al.* [23]. To determine the relative prevalence of canonical stimulatory and inhibitory CpG motifs in the genomic sequences of the various bacteria, we employed a two-step approach. Genbank-retrieved FASTA formatted text files were uploaded to <http://insilico.ehu.es/> and the frequency of all 4096 possible hexamers were determined as described by Bikandi *et al.* [24]. This information and the general composition of each genome was then entered into Microsoft Excel, and common place formulas were used to count the occurrence of specific CpG motifs. As a measure of SP and NM genome's potential for *TLR9* stimulation, the CpG index is used to facilitate comparison of immunostimulatory potentials regardless of genome size, G + C content and overall CpG suppression and was calculated by comparing the frequency of stimulatory and inhibitory CpG motifs [23].

Table 1A. *TLR9+2848* Genotype Distribution in Cases and Controls

<i>TLR9+2848</i>	N	GG Wild type (%)	GA Heterozygous (%)	AA mutant (%)
Total BM ^a	460	110 (23.9)	214 (46.5)	136 (29.6)
<i>S. pneumoniae</i>	80	17 (21.3)	36 (45.0)	27 (33.8)
<i>N. meningitidis</i> ^b	380	93 (24.5)	178 (46.8)	109 (28.7)
Controls*	392	66 (16.8)	192 (49.0)	134 (34.2)

^a *TLR9+2848* mutant allele (genotypes GA or AA) was significantly decreased in BM patients compared to controls (p: .0110, OR .6, 95% CI .5 - .9).

^b *TLR9+2848* mutant allele was most significantly decreased in MM patients compared to healthy controls (p: .0098, OR: .6, 95% CI: .4 - .9).

Table 1B. *TLR9*-1237 Genotype Distribution in Cases and Controls

<i>TLR9</i> -1237	N	TT Wildtype (%)	TC Heterozygous (%)	CC mutant (%)
Total BM	464	341 (73.5)	113 (24.4)	10 (2.2)
<i>S. pneumoniae</i>	82	61 (74.4)	20 (24.4)	1 (1.2)
<i>N. meningitidis</i>	382	280 (24.5)	93 (24.4)	9 (2.4)
Controls	392	274 (69.9)	112 (28.6)	6 (1.5)

RESULTS

Susceptibility analysis

Single nucleotide polymorphisms analysis

For susceptibility analysis, BM patients were compared to the control group. The PM and MM groups were also separately compared to the controls. PM and MM patients were also compared to each other to discover associations between SNPs and susceptibility to a specific pathogen. The results are summarized in *Table 1A* and *1B*. Because concentrations and quality of DNA varied among samples, some samples that could not be genotyped after 3 or more TaqMan analyses were excluded. This explains the difference in numbers of included patients and numbers of genotyped patients in the tables. Carriage of the *TLR9* +2848 mutant allele (genotypes GA or AA) was significantly decreased in BM patients compared with controls ($p = 0.011$, OR 0.6, 95% CI 0.5–0.9).

Carriage of the *TLR9* +2848 mutant allele was also significantly decreased in MM patients compared with healthy controls ($p = 0.0098$, OR 0.6, 95% CI 0.4–0.9), but the genotype distribution in PM patients did not differ significantly from healthy controls. There were no significant differences between PM and MM patients. The *TLR9* -1237 SNP was not significantly associated with the susceptibility to BM.

Haplotype analysis

Genotyping of both *TLR9* -1237 and *TLR9* +2848 allows all four locus haplotypes to be distinguished. The results are summarized in *Table 2*. *TLR9* haplotype I was significantly increased in BM patients compared with the control group; ($p = 0.0348$, OR 1.2, 95% CI 1.0–1.5). *TLR9* haplotype I was significantly increased in the MM patients compared to healthy controls; ($p = 0.0237$, OR 1.3, 95% CI 1.0–1.5). There were no significant differences in haplotype I distribution between the PM group and controls, neither between the PM and the MM group. For the distribution of other

haplotypes we found no significant differences between the control group and the total group of BM patients, nor between the PM and MM patients separately.

Table 2. Frequencies of *TLR9* Haplotypes in Cases and Controls

<i>TLR9</i> haplotypes					
(2n)	I ^a (%)	II ^b (%)	III ^c (%)	IV ^d (%)	
Total BM*	914	419 (45.8)	363 (39.7)	124 (13.6)	8 (0.9)
<i>S. pneumoniae</i>	160	69 (43.1)	69 (43.1)	21 (13.1)	1 (0.6)
<i>N. meningitidis</i> *	754	350 (46.4)	294 (39.0)	103 (13.7)	7 (0.9)
Controls*	784	319 (40.7)	341 (43.5)	118 (15.1)	6 (0.8)

^{a-d} Haplotypes as defined by Lazarus *et al.* [19]

**TLR9* haplotypes I was significantly increased in BM patients compared to the control group; (p: .0348, OR 1.2, 95% CI 1.0 – 1.5). *TLR9* haplotype I was significantly increased in the MM patients compared to healthy controls; (p: .0237, OR 1.3, 95% C: 1.0 – 1.5).

In silico analysis

In *Table 3* we summarized CpG indices for causative agents of BM. Positive CpG indices indicate immunostimulatory properties, whereas negative values indicate immunoinhibitory properties. Increasing values for the CpG indices indicate stronger effects. SP showed a mildly immunostimulatory potential with a CpG index of 8.6. This was comparable to another causative agent of meningitis, *Haemophilus Influenzae*. Interestingly, for NM we found a very strong immunoinhibitory CpG index of -106.8.

Table 3. Results of the In Silico Analysis

Bacterium	CpG motif deviation ^a						
	Genome				Consensus motifs ^b		
	Size (Mb)	G 1 C (%)	CPG/kb ^c	Total CpG ^d	Stimulatory ^e	Inhibitory ^f	CpG index ^g
<i>Streptococcus pneumoniae</i>	2.22	39.5	78.0	69.5	82.4	66.5	8.6
<i>Neisseria meningitidis</i>	2.27	51.5	132.7	130.6	78.4	140.0	-106.8
<i>Haemophilus influenzae</i>	1.91	38.2	72.8	109.1	105.5	96.4	7.2

^a Deviations in specified motif occurrences relative to those expected based on genomic G 1 C content.

^b Consensus stimulatory and inhibitory CpG hexamer motifs are based on published analysis. They are used in this table as indicators of the general frequencies of stimulatory and inhibitory CpG hexamer motifs in each genome.

^c Number of CpG hexamer motifs (NNCGNN) occurring in each genome normalized to 100 kb.

^d Total frequency of CpG hexamer motifs (NNCGNN); expected number based on nucleotide composition of the genome.

^e Frequency of consensus stimulatory hexamer motifs (RRCGY).^g

^f Frequency of consensus inhibitory hexamer motifs (NCCGNN and NNCGRN).

^g Calculated from frequencies of stimulatory less inhibitory consensus hexamer motifs as an indicator of stimulation versus inhibition multiplied by total CpG number (normalized to 1 kb) and the overall frequency of CpG (NNCGNN).

DISCUSSION

This study describes a strong association between *TLR9* SNPs and BM in a large cohort of BM survivors. Based on our findings we propose that *TLR9* genetic variation can compensate for the inhibitory effects of Neisserial CpG DNA resulting in a reduced susceptibility for MM.

Carriage of the *TLR9* +2848-A mutant decreases the susceptibility to BM, specifically MM ($p = 0.0098$). Carriage of *TLR9* haplotype I was associated with an increased risk to develop MM. This can be explained for the greatest part by the fact that this haplotype does not contain the protective *TLR9* +2848-A allele. Knockout (KO) mice data showed that the presence of the *TLR9* gene is essential to combat meningococcal infection [25]. The *in silico* analysis showed a very strong immunoinhibitory potential (CpG index of -106.8) for the DNA from NM. Combining the SNP, haplotype, KO-mice data, and *in silico* analyses, one might hypothesize that the *TLR9* +2848-A mutant results in an upregulation of *TLR9* induced immune response, compensating for the strong inhibitory potential of NM CpG DNA.

Besides activation of microglia and astrocytes [5, 26] and complement mediated bacterial lysis [27] also antibacterial responses like antimicrobial peptides and reactive nitrogen and oxygen radicals are relevant in the pathogenesis of BM. A recent study using human embryonic kidney cells reported *TLR9* activation by NM [28]. Sjolinder *et al.* reported that *TLR9* *-/-* mice displayed reduced survival, elevated levels of bacteremia, and reduced bactericidal activity *in vivo* compared with wild type mice during meningococcal bacteremia [25]. They also found that antigen-presenting cells relied entirely on *TLR9* to induce activation of signal transduction and induction of proinflammatory cytokine gene expression. Together, these studies show the importance of *TLR9* upon bacteremia with NM. We propose that the *TLR9* SNPs we described are able to enhance *TLR9* function and prevent high levels of bacteremia, an important step in the pathophysiology of BM.

Once inside the CNS, bacteria are recognized by antigen presenting astrocytes and microglia. Intracellular recognition of (bacterial) CpG motifs leads to immune activation inside the CNS by the proinflammatory cytokines tumor necrosis factor alpha (TNF- α) and interleukin 6 (IL-6) and the granulocytic chemoattractant IL-8 [29]. Tauber *et al.* studies the effects of continuous intrathecal CpG DNA exposure to the brain of *TLR9* *-/-* mice in the CNS. Microglia from *TLR9* *-/-* mice could not be activated by CpG DNA. Brains of wild-type mice showed more pronounced neuronal damage with microglial activation and reactive astrogliosis. These results suggest that the unfavorable effects of CpG DNA in the brain are dependent on *TLR9* and may contribute to neuroinflammation [30]. Very recently, Ribes *et al.* reported increased phagocytic activity by murine microglia activated with agonists for TLR2, -4, and -9

upon exposure by SP [31]. We speculate that this might also happen in MM and that the *TLR9* SNPs we described result in enhanced phagocytosis by microglia inside the CNS. In contrast, by using mice with single- or combined deficiencies of *TLR2*, *TLR4*, or *TLR9*, Klein *et al.* demonstrated that TLR2 and TLR4 play an essential role in PM, whereas additional *TLR9* deficiency did not result in further attenuation of the inflammatory reaction observed *TLR2-TLR4*-double deficient mice [32]. We did not find this protective *TLR9* effect in our SP cohort either.

The strength of this study is that we focused exclusively on meningitis patients to find the host genetic determinant of this specific disease. We recruited a large group of MM survivors and found very significant results. Our cohort of PM survivors was relatively small however, and we could not find significant results for this group. In our study we used a healthy adult control group, but we have no specific information on a history of BM. However, since the maximum incidence of BM in the Netherlands was low (incidence per 100.000 inhabitants varied between 4.8 and 1.6 during the period 1999–2008 in the Netherlands) [2], we considered it a representative control group for immunogenetic research on BM. DNA from children with fatal BM who suffered the most severe infections was not available. We expect, however, that including DNA of fulminant cases will only make the association we found for susceptibility to BM stronger, although future studies focusing on the severity of BM specifically would be of interest in this respect but these cases are rare and collecting 400 cases would be near to impossible.

The results we found in this study will guide future research on genetic studies in susceptibility to and severity of BM in our cohort. Genetic studies can reveal relevant SNPs in immune response genes influencing the pathogenesis of BM. This might also identify potential drug targets. For example, TLR activation leads to cytokine production mostly via nuclear factor kappa B (NFκB) and the mitogen-activated proteins kinase (MAPK) family. Clinical trials are prepared to block NFκB and MAPK transcription [33, 34]. However, none of such potential drugs are used for clinical practice yet. Identification of specific SNPs could be used to develop a customized treatment fitting the patient's genetic profile and decreasing side effects. Patients carrying SNPs known to influence the immune response might receive medication to either stimulate or inhibit this response. Better understanding of the role of immunogenetics in the pathogenesis of BM may allow the prediction of individual risk to develop BM, enabling a tailored approach to follow up. Besides clinical factors, host-genetic factors (SNPs) may be valuable markers for the prediction of long term consequences of BM including hearing loss, and neuropsychological complications [17, 18, 35] in an early stage of disease. Multiple associations have already been described between SNPs in innate immunity genes and the outcome of SP and NM infections [36–38].

Three important steps have to be made to translate these findings into patient management: (1) the study has to be confirmed and additional SNPs in other genes have to be added in a genetic trait to obtain synergy in the prediction of susceptibility or protection to BM, (2) this genetic trait has to be added to potentially strengthen current clinical prediction rules on complication rates after BM which include hearing loss and academic and behavioral limitation [16–18], and (3) strategies to promote a faster path for genetic knowledge from bench to bedside have to be implemented. The various stakeholders in public health play a key role in translating the implications of genomics such as deriving from molecular epidemiology and host-pathogen genomics. This knowledge will not only enable clinical interventions but also health promotion messages and disease prevention programs to be targeted at susceptible individuals as well as subgroups of the population based on their genomic profile (personalized healthcare) [39, 40]. The field involved in this translation is called Public Health Genomics, which has as major task in “the responsible and effective translation of genome-based knowledge and technologies into public policy and health services for the benefit of population health” (Bellagio statement, 2005: see www.graphint.org for details).

CONCLUSIONS

In summary, our findings provide another step toward the use of SNPs in immune response genes as valuable markers to assess the risk to develop BM. Additional immunogenetic studies with larger sample sizes, validation cohorts, and genotyping including multiple synergistic genes and more complete haplotype information will help to elucidate the pathophysiology of meningitis and to explain the inter-patient variability in BM, largely depending on the ability of the (innate) immune system to clear the infection, with as an ultimate goal to predict the course and outcome of infection.

ACKNOWLEDGEMENTS

The authors acknowledge Jolein Pleijster at the Laboratory of Immunogenetics of the VU University Medical Center for expert technical assistance and Rogier de Jonge, neonatologist at the department of Pediatrics of the VU University Medical Center, together with Arisja Mauritz, medical student of the VU University for their excellent support in data inclusion.

REFERENCES

1. Klein M, Pfister HW, Leib SL, Koedel U. Therapy of community acquired acute bacterial meningitis: the clock is running. *Expert Opin Pharmacother* 2009; 10:2609–23.
2. van der Ende A, Spanjaard L. Bacterial meningitis in the Netherlands annual report 2008, Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM), published 2009.
3. Odigwe C. West Africa has worst meningitis epidemic for 10 years. *Br Med J* 2009; 338:b1638.
4. Koedel U. Toll-like receptors in bacterial meningitis. *Curr Top Microbiol Immunol* 2009; 336:15–40.
5. Jack CS, Arbour N, Manusow J, *et al.* TLR signaling tailors innate immune responses in human microglia and astrocytes. *J Immunol* 2005; 175:4320–30.
6. Hemmi H, Takeuchi O, Kawai T, *et al.* A Toll-like receptor recognizes bacterial DNA. *Nature* 2000; 408:740–5.
7. Brouwer MC, de GJ, Heckenberg SG, Zwinderman AH, Van Der Pol T, van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. *Lancet Infect Dis* 2009; 9:31–44.
8. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. *Clin Sci (Lond)* 2008; 114:347–60.
9. Faber J, Meyer CU, Gemmer C, *et al.* Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. *Pediatr Infect Dis J* 2006; 25:80–1.
10. Smirnova I, Mann N, Dols A, *et al.* Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. *Proc Natl Acad Sci U S A* 2003; 100:6075–80.
11. Yuan FF, Marks K, Wong M, *et al.* Clinical relevance of TLR2, TLR4, CD14 and FcγRIIA gene polymorphisms in *Streptococcus pneumoniae* infection. *Immunol Cell Biol* 2008; 86:268–70.
12. Picard C, Puel A, Bonnet M, *et al.* Pyogenic bacterial infections in humans with IRAK-4 deficiency. *Science* 2003; 299:2076–9.
13. Allen A, Obaro S, Bojang K, *et al.* Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. *Pediatr Infect Dis J* 2003; 22:1018–9.
14. Haralambous E, Weiss HA, Radałowicz A, Hibberd ML, Booy R, Levin M. Sibling familial risk ratio of meningococcal disease in UK Caucasians. *Epidemiol Infect* 2003; 130:413–8.
15. Lammers KM, Ouburg S, Morre SA, *et al.* Combined carriage of *TLR9-1237C* and *CD14-260T* alleles enhances the risk of developing chronic relapsing pouchitis. *World J Gastroenterol* 2005; 11:7323–9.
16. Koomen I, Grobbee DE, Jennekens-Schinkel A, Roord JJ, van Furth AM. Parental perception of educational, behavioural and general health problems in school-age survivors of bacterial meningitis. *Acta Paediatr* 2003; 92:177–85.
17. Koomen I, Grobbee DE, Roord JJ, Donders R, Jennekens-Schinkel A, van Furth AM. Hearing loss at school age in survivors of bacterial meningitis: assessment, incidence, and prediction. *Pediatrics* 2003; 112:1049–53.
18. Koomen I, Raat H, Jennekens-Schinkel A, Grobbee DE, Roord JJ, van FM. Academic and behavioral limitations and health-related quality of life in school-age survivors of bacterial meningitis. *Qual Life Res* 2005; 14:1563–72.

19. Lazarus R, Klimecki WT, Raby BA, *et al.* Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (*TLR9*): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. *Genomics* 2003; 81:85–91.
20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 2001 Apr; 68:978–89.
21. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. *Am J Hum Genet* 2003 Nov; 73:1162–9.
22. Clayton DG. SNP-HAP. Available at: <http://www-gene.cimr.cam.ac.uk/>; 2002 Available from: URL: <http://www-gene.cimr.cam.ac.uk/clayton/software/>.
23. Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. *J Virol* 2003; 77:11158–69.
24. Bikandi J, San MR, Rementeria A, Garaizar J. In silico analysis of complete bacterial genomes: PCR, AFLP-PCR and endonuclease restriction. *Bioinformatics* 2004 Mar 22; 20:798–9.
25. Sjolinder H, Mogensen TH, Kilian M, Jonsson AB, Paludan SR. Important role for Toll-like receptor 9 in host defense against meningococcal sepsis. *Infect Immun* 2008; 76:5421–8.
26. Kim KS. Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. *Nat Rev Neurosci* 2003; 4:376–85.
27. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. Interactions between *Neisseria meningitidis* and the complement system. *Trends Microbiol* 2007; 15:233–40.
28. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. *J Leukoc Biol* 2006; 80:267–77.
29. Butchi NB, Du M, Peterson KE. Interactions between TLR7 and *TLR9* agonists and receptors regulate innate immune responses by astrocytes and microglia. *Glia* 2010; 58:650–64.
30. Tauber SC, Ebert S, Weishaupt JH, Reich A, Nau R, Gerber J. Stimulation of Toll-like receptor 9 by chronic intraventricular unmethylated cytosine-guanine DNA infusion causes neuroinflammation and impaired spatial memory. *J Neuropathol Exp Neurol* 2009; 68:1116–24.
31. Ribes S, Ebert S, Regen T, *et al.* Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated *Streptococcus pneumoniae* by murine microglia. *Infect Immun* 2010; 78:865–71.
32. Klein M, Obermaier B, Angele B, *et al.* Innate immunity to pneumococcal infection of the central nervous system depends on toll-like receptor (TLR) 2 and TLR4. *J Infect Dis* 2008; 198:1028–36.
33. Khor CC, Chapman SJ, Vannberg FO, *et al.* A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteraemia, malaria and tuberculosis. *Nat Genet* 2007; 39:523–8.
34. Carpenter S, O'Neill LA. How important are Toll-like receptors for antimicrobial responses? *Cell Microbiol* 2007; 9:1891–901.
35. Koomen I, van Furth AM, Kraak MA, Grobbee DE, Roord JJ, Jennekens-Schinkel A. Neuropsychology of academic and behavioural limitations in school-age survivors of bacterial meningitis. *Dev Med Child Neurol* 2004; 46:724–32.
36. Balding J, Healy CM, Livingstone WJ, *et al.* Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease? *Genes Immun* 2003; 4:533–40.

37. Domingo P, Muniz-Diaz E, Baraldes MA, *et al.* Relevance of genetically determined host factors to the prognosis of meningococcal disease. *Eur J Clin Microbiol Infect Dis* 2004; 23:634–7.
38. Schaaf BM, Boehmke F, Esnaashari H, *et al.* Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. *Am J Respir Crit Care Med* 2003; 168:476–80.
39. Brand A, Brand H, Schulte in den BT. The impact of genetics and genomics on public health. *Eur J Hum Genet* 2008; 16:5–13.
40. Brand A. Integrative genomics, personal-genome tests and personalized healthcare: the future is being built today. *Eur J Hum Genet* 2009; 17:977–8.

